A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.
Condition(s):New-onset Type 1 DiabetesLast Updated:December 22, 2023Terminated
Hide Studies Not Open or Pending
Condition(s):New-onset Type 1 DiabetesLast Updated:December 22, 2023Terminated
Condition(s):Coronary Artery Disease; Myocardial InfarctionLast Updated:March 1, 2023Completed
Condition(s):Endometrial Neoplasms; Endometrial Neoplasm Malignant; Endometrial Neoplasm Malignant Stage I; Carcinoma, Endometrioid; Fertility PreservationLast Updated:July 14, 2023Recruiting
Condition(s):ObesityLast Updated:February 23, 2024Recruiting
Condition(s):Non-Alcoholic SteatohepatitisLast Updated:March 3, 2022Withdrawn
Condition(s):Pre-Eclampsia; Pregnancy; HELLP Syndrome; Intrauterine Growth RestrictionLast Updated:August 27, 2018Unknown status
Condition(s):Autism Spectrum DisorderLast Updated:April 6, 2022Completed
Condition(s):Muscle Degeneration; Body Weight Changes; Walking, DifficultyLast Updated:August 21, 2023Completed
Condition(s):Colorectal CancerLast Updated:March 13, 2018Completed
Condition(s):Long Covid-19Last Updated:April 4, 2022Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.